Kanakeswary Karisnan* and Sellaiah Sithambaram

Faculty of Medicine, QUEST International University, Ipoh, Malaysia

*Corresponding Author: Kanakeswary Karisnan, Faculty of Medicine, QUEST International University, Ipoh, Malaysia.

Received: May 25, 2022; Published: June 16, 2022

Abstract

Lung cancer is an aggressive and heterogeneous disease. A global epidemic of lung cancer in women is sweeping the globe. Although cigarette smoking is the leading cause of lung cancer in both women and men, several studies have found significant gender differences. Lung cancer is becoming more common among nonsmokers, particularly Asian women. This mini review summarizes the epidemic of lung cancer in Asian women and the importance of screening with the use of low-dose CT for early detection and thus reduce lung cancer mortality rate.

Keywords:Lung cancer, women, non-smoker, screening, Low-dose CT

References

1. Sung H., et al. “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries”. CA Cancer Journal of Clinics3 (2021): 209-249.
2. Cheng T Y., et al. “The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics”. Journal of Thoracic Oncology10 (2016): 1653a1671.
3. Rafiemanesh H., et al. “Epidemiology, incidence and mortality of lung cancer and their relationship with the development index in the world”. Journal of Thoracic Disease6 (2016): 1094-1102.
4. Baldwin D. “Socioeconomic position and delays in lung cancer diagnosis: should we target the more deprived?” Thorax 5 (2017): 393-395.
5. Huang J., et al. “Distribution, Risk Factors, and Temporal Trends for Lung Cancer Incidence and Mortality: A Global Analysis”. Chest 4 (2022): 1101-1111.
6. Xue Y., et al. “Association between cooking oil fume exposure and lung cancer among Chinese nonsmoking women: a meta-analysis”. OncoTargets and Therapy 9 (2016): 2987-2992.
7. Smolle E and Pichler M. “Non-Smoking-Associated Lung Cancer: A distinct Entity in Terms of Tumor Biology, Patient Characteristics and Impact of Hereditary Cancer Predisposition”. Cancers (Basel)2 (2019): 204.
8. The Global Cancer Observatory.
9. Hoffman R M and Sanchez R. “Lung Cancer Screening”. Medical Clinics of North America4 (2017): 769-785.
10. Becker N., et al. “Lung cancer mortality reduction by LDCT screening-Results from the randomized German LUSI trial”. International Journal of Cancer6 (2020): 1503-1513.
11. Zhang Y., et al. “Results of low-dose computed tomography as a regular health examination among Chinese hospital employees”. The Journal of Thoracic and Cardiovascular Surgery 160 (2020): 824-831.
12. Veronesi G., et al. “Recommendations for Implementing Lung Cancer Screening with Low-Dose Computed Tomography in Europe”. Cancers (Basel)6 (2020).
13. Chu G., et al. “Serum and blood based biomarkers for lung cancer screening: a systematic review”. BMC Cancer 1 (2018): 181.
14. Barta J A., et al. “Global Epidemiology of Lung Cancer”. Annals of Global Health1 (2019): 8.
15. MacRosty C R and Rivera MP. “Lung Cancer in Women: A Modern Epidemic”. Clinical Chest Medicine1 (2020): 53-65.
16. Stapelfeld C., et al. “Sex-specificity in lung cancer risk”. International Journal of Cancer9 (2022): 2376-2382.
17. Ragavan M and Patel M. “The evolving landscape of sex-based differences in lung cancer: a distinct disease in Women”. European Respiratory Review 163 (2022): 210100.
18. Kim J., et al. “Lung Cancer: Diagnosis, Treatment Principles, and Screening”. American Family Physician5 (2022): 487-494.
19. Duffy M J and O’Byrne K. “Tissue and Blood Biomarkers in Lung Cancer: A Review”. Advances in Clinical Chemistry 86 (2018): 1-21.
20. Lemjabbar-Alaoui H., et al. “08. 00. Lung cancer: Biology and treatment options”. Biochimica et Biophysica Acta 2 (2015): 189-210.
21. Villalobos P and Wistuba II. “Lung Cancer Biomarkers”. Hematology/Oncology Clinics of North America 1 (2017): 13-29.
22. Harrison P T., et al. “Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer”. Seminars in Cancer Biology 61 (2020): 167-179.
23. Bebb D G., et al. “Crizotinib inhibition of ROS1-positive tumours in advanced non-small-cell lung cancer: a Canadian perspective”. Current Oncology4 (2019): E551-e557.
24. Khan M., et al. “ALK Inhibitors in the Treatment of ALK Positive NSCLC”. Frontiers in Oncology 8 (2019): 557.
25. Huang J and Teng X. “Expression of PD-L1 for predicting response to immune checkpoint inhibitors in metastatic urothelial carcinoma: a systematic review and meta-analysis”. Current Oncology6 (2020): e656-e663.

Citation

Citation: Kanakeswary Karisnan and Sellaiah Sithambaram. “Lung Cancer in Asian Women". Acta Scientific Women's Health 4.7 (2022): 48-52.

Copyright

Copyright: © 2022 Kanakeswary Karisnan and Sellaiah Sithambaram. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.